ArticleAntimicrobial agents and chemotherapy2015
Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Article
- Micafungin exposure drives multidrug resistance inbioRxiv : the preprint server for biology · 2026Article
- A Calcineurin Inhibitor as an Enhancer ofACS omega · 2026Article
- Emerging antifungal resistance in Candida parapsilosis: the end of the innocence.npj antimicrobials and resistance · 2025Review
- Article
- Phenotypic and genotypic characterization of Candida parapsilosis complex isolates from a Lebanese hospital.Scientific reports · 2025Article
- Insights into the origin, hybridisation and adaptation of Candida metapsilosis hybrid pathogens.PLoS pathogens · 2025Article
- Threats from theMicrobiology and molecular biology reviews : MMBR · 2024Review
- A new PK/PD target for assessing efficacy of micafungin against Candida parapsilosis.The Journal of antimicrobial chemotherapy · 2024Article
- Candida parapsilosis complex in the clinical setting.Nature reviews. Microbiology · 2024Review
- Decreased echinocandin susceptibility inEmerging microbes & infections · 2023Article
- Review
- Genomic epidemiology of human candidaemia isolates in a tertiary hospital.Microbial genomics · 2023Article
- Aneuploidy enables cross-tolerance to unrelated antifungal drugs inFrontiers in microbiology · 2023Article
- Determinants of fluconazole resistance and echinocandin tolerance inEmerging microbes & infections · 2022Article
- Evolution of Fluconazole Resistance Mechanisms and Clonal Types ofAntimicrobial agents and chemotherapy · 2022Article
- Antimicrobial Resistance and Biofilms Underlying Catheter-Related Bloodstream Coinfection byAntibiotics (Basel, Switzerland) · 2022Article
- Article
- Pan-Echinocandin ResistantJournal of fungi (Basel, Switzerland) · 2022Article
- Evidence of Fluconazole-Resistant Candida parapsilosis Genotypes Spreading across Hospitals Located in Madrid, Spain and Harboring the Y132F ERG11p Substitution.Antimicrobial agents and chemotherapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated FKS1 and FKS2 mutations in Candida parapsilosis bloodstream isolates and correlated them with the echinocandin MIC values determined by guidelines in CLSI document M27-A3 and the YeastOne panel. All mutations detected were outside hot spot (HS) regions. The F1386S mutation detected in an isolate that was resistant by the YeastOne panel but not by the M27-A3 guidelines might be implicated in echinocandin resistance. Further studies are needed to confirm the implication of the F1386S mutation and to elucidate the capability of the M27-A3 guidelines to detect echinocandin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.